Repligen (NASDAQ:RGEN) Rating Lowered to Buy at BidaskClub

Repligen (NASDAQ:RGEN) was downgraded by stock analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Friday, BidAskClub reports.

Several other analysts have also recently weighed in on the stock. Stifel Nicolaus lifted their price objective on shares of Repligen from $105.00 to $116.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Stephens lifted their price objective on shares of Repligen from $112.00 to $114.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. Finally, HC Wainwright dropped their price objective on shares of Repligen from $110.00 to $100.00 and set a “buy” rating for the company in a research note on Monday. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Repligen currently has an average rating of “Buy” and a consensus target price of $107.14.

NASDAQ RGEN opened at $91.41 on Friday. The firm has a 50-day moving average of $95.70 and a 200-day moving average of $89.36. The company has a debt-to-equity ratio of 0.25, a quick ratio of 12.15 and a current ratio of 13.28. The stock has a market cap of $4.93 billion, a PE ratio of 207.75, a P/E/G ratio of 3.93 and a beta of 1.34. Repligen has a 52-week low of $52.87 and a 52-week high of $109.94.

Repligen (NASDAQ:RGEN) last posted its earnings results on Thursday, February 20th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.18 by $0.02. The company had revenue of $69.47 million during the quarter, compared to analysts’ expectations of $68.37 million. Repligen had a net margin of 7.92% and a return on equity of 5.82%. Repligen’s quarterly revenue was up 33.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.21 EPS. As a group, analysts predict that Repligen will post 1.1 EPS for the current fiscal year.

In other Repligen news, VP Ralf Kuriyel sold 450 shares of Repligen stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $88.35, for a total value of $39,757.50. Following the completion of the sale, the vice president now owns 29,079 shares in the company, valued at approximately $2,569,129.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Anthony Hunt sold 11,735 shares of Repligen stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $91.56, for a total transaction of $1,074,456.60. Following the completion of the sale, the chief executive officer now owns 231,148 shares of the company’s stock, valued at approximately $21,163,910.88. The disclosure for this sale can be found here. Insiders sold a total of 54,125 shares of company stock valued at $5,039,228 in the last quarter. Corporate insiders own 1.70% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the business. Barclays PLC increased its holdings in Repligen by 123.2% in the 4th quarter. Barclays PLC now owns 77,605 shares of the biotechnology company’s stock valued at $7,178,000 after buying an additional 42,843 shares during the period. Castleark Management LLC increased its holdings in Repligen by 193.5% in the 3rd quarter. Castleark Management LLC now owns 75,780 shares of the biotechnology company’s stock valued at $5,812,000 after buying an additional 49,960 shares during the period. First Trust Advisors LP increased its holdings in Repligen by 17.8% in the 4th quarter. First Trust Advisors LP now owns 51,470 shares of the biotechnology company’s stock valued at $4,761,000 after buying an additional 7,787 shares during the period. Millennium Management LLC increased its holdings in Repligen by 6.4% in the 3rd quarter. Millennium Management LLC now owns 25,685 shares of the biotechnology company’s stock valued at $1,969,000 after buying an additional 1,550 shares during the period. Finally, Voya Investment Management LLC increased its holdings in Repligen by 4.5% in the 3rd quarter. Voya Investment Management LLC now owns 519,407 shares of the biotechnology company’s stock valued at $39,833,000 after buying an additional 22,586 shares during the period. 83.87% of the stock is currently owned by hedge funds and other institutional investors.

About Repligen

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

See Also: What is a balanced fund?

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.